IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Administration of rHDL-0 (16.3 ± 3.0%) and rHDL-2 (14.9 ± 1.1%) resulted in a non-significant (p > 0.05) reduction in the IL-6-stained area induced by the CML compared to the CML + PBS-injected group.